{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:20:34Z","timestamp":1759332034149,"version":"3.37.3"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T00:00:00Z","timestamp":1462752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81172110"],"award-info":[{"award-number":["No. 81172110"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National High Technology Research and Development Program","award":["No. 2012AA 02A 504"],"award-info":[{"award-number":["No. 2012AA 02A 504"]}]},{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"crossref","award":["No. 2014CBA02002"],"award-info":[{"award-number":["No. 2014CBA02002"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0154679","type":"journal-article","created":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T17:28:32Z","timestamp":1462814912000},"page":"e0154679","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors"],"prefix":"10.1371","volume":"11","author":[{"given":"Tiantian","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongwu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,5,9]]},"reference":[{"article-title":"WHO classification of tumours of the digestive system","year":"2010","author":"FT Bosman","key":"ref1"},{"issue":"18","key":"ref2","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after &quot;carcinoid&quot;: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"JC Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3747\/co.v17i3.484","article-title":"Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group","volume":"17","author":"W Kocha","year":"2010","journal-title":"Curr Oncol"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8","article-title":"Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors","volume":"86","author":"E Bajetta","year":"1999","journal-title":"Cancer"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ejca.2011.08.012","article-title":"Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments","volume":"48","author":"CM Korse","year":"2012","journal-title":"Eur J Cancer"},{"issue":"9","key":"ref6","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1245\/s10434-010-1006-3","article-title":"Chromogranin A\u2014biological function and clinical utility in neuro endocrine tumor disease","volume":"17","author":"IM Modlin","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.5301\/JBM.2008.1664","article-title":"Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors","volume":"19","author":"L Ferrari","year":"2004","journal-title":"Int J Biol Markers"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1677\/joe.0.1770337","article-title":"A comparison between three commercial kits for chromogranin A measurements","volume":"177","author":"M Stridsberg","year":"2003","journal-title":"J Endocrinol"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000333853","article-title":"Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients","volume":"95","author":"WC Chou","year":"2012","journal-title":"Neuroendocrinology"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2265.2004.02030.x","article-title":"Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours","volume":"60","author":"D Nehar","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1080\/00365520903082432","article-title":"Small intestinal neuroendocrine tumors: prognostic factors and survival","volume":"44","author":"DS Bergestuen","year":"2009","journal-title":"Scand J Gastroenterol"},{"issue":"23","key":"ref12","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","article-title":"Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas","volume":"22","author":"MA Kouvaraki","year":"2004","journal-title":"J Clin Oncol"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.ejca.2011.11.005","article-title":"Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?","volume":"48","author":"T Walter","year":"2012","journal-title":"Eur J Cancer"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12032-013-0664-y","article-title":"Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas","volume":"30","author":"ZH Lu","year":"2013","journal-title":"Med Oncol"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"year":"2010","author":"SB Edge","key":"ref16"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/egh.12.15","article-title":"Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors","volume":"6","author":"S Singh","year":"2012","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"27","key":"ref18","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1097\/MD.0000000000000247","article-title":"Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm","volume":"93","author":"YH Wang","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.mpa.0000235302.73615.d4","article-title":"Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency","volume":"33","author":"EA Woltering","year":"2006","journal-title":"Pancreas"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1677\/ERC-07-0001","article-title":"Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study","volume":"14","author":"MC Zatelli","year":"2007","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"ref21","first-page":"184","article-title":"Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina","volume":"39","author":"SH Belli","year":"2009","journal-title":"Acta Gastroenterol Latinoam"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.6004\/jnccn.2015.0011","article-title":"Neuroendocrine tumors, version 1.2015","volume":"13","author":"MH Kulke","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 1","key":"ref23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000201402","article-title":"The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours","volume":"57","author":"B Eriksson","year":"1996","journal-title":"Digestion"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.5301\/JBM.2011.8327","article-title":"Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study","volume":"26","author":"D Vezzosi","year":"2011","journal-title":"Int J Biol Markers"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/00365520410003362","article-title":"Clinical significance of elevated serum chromogranin A levels","volume":"39","author":"U Syversen","year":"2004","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"ref26","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/sj.bjc.6605618","article-title":"Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours","volume":"102","author":"NC Turner","year":"2010","journal-title":"Br J Cancer"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1677\/ERC-09-0042","article-title":"Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study","volume":"16","author":"A Ahmed","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"ref28","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.cgh.2008.02.052","article-title":"Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors","volume":"6","author":"R Arnold","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s10620-006-9345-4","article-title":"Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors","volume":"51","author":"TE Clancy","year":"2006","journal-title":"Dig Dis Sci"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1210\/jc.2011-0666","article-title":"Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus","volume":"96","author":"JC Yao","year":"2011","journal-title":"J Clin Endocrinol Metab"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0154679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T20:39:42Z","timestamp":1589661582000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0154679"}},"subtitle":[],"editor":[{"given":"Stephane","family":"Gasman","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,9]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0154679","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2016,5,9]]}}}